Abbott Gains FDA Approval for Tendyne™, Strengthening Its Minimally Invasive Heart Portfolio

Abbott Laboratories (NYSE:ABT) has received FDA approval today for its Tendyne™ transcatheter mitral valve replacement (TMVR) system, the first device of its kind approved in the US to treat mitral valve disease without open-heart surgery.

Tendyne is specifically designed for patients who are not suitable candidates for surgical valve repair or replacement. The product perfectly fits the aging population trends and the demand for less invasive treatments, implying that it could become a significant cash cow for ABT.

The approval gives Abbott Laboratories a competitive edge in the growing structural heart market, valued at around $15 billion globally, and will likely accelerate the company’s growth. The Medical Devices segment accounts for 47% of total revenue in Q1 2025 and is the fastest growing segment – the US revenues posted 15% growth YoY, meaning that the segment is already central to the growth story.

The announcement comes weeks after ABT reiterated its organic revenue growth guidance at 7.5% to 8.5% for FY2025, while the street consensus expects only 6.4% total revenue growth. This raises the odds of positive surprises later in the year, which could propel ABT shares even higher. For reference, ABT already outperforms the broad market by a massive 17% year-to-date, highlighting its strong momentum.

Abbott Laboratories is a global healthcare company that owns a portfolio of life-changing technologies across diagnostics, medical devices, nutritionals, and branded generic medicines.

READ NEXT: 12 Most Popular Stocks on Robinhood in 2025 and 11 Oversold Global Stocks to Buy According to Hedge Funds